{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,11]],"date-time":"2026-10-11T14:09:18Z","timestamp":1791727758906,"version":"4.3.4"},"reference-count":46,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,3,17]],"date-time":"2026-03-17T00:00:00Z","timestamp":1773705600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,3,17]],"date-time":"2026-03-17T00:00:00Z","timestamp":1773705600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Med"],"DOI":"10.1186\/s12916-026-04729-8","type":"journal-article","created":{"date-parts":[[2026,3,17]],"date-time":"2026-03-17T00:03:22Z","timestamp":1773705802000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Oncostatin-M ligand-based CAR-T therapy displays robust anti-tumor activity against osteosarcoma"],"prefix":"10.1186","volume":"24","author":[{"given":"Daniel","family":"Feinberg","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vinayak","family":"Uppin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Saada","family":"Eid","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claire","family":"Fritz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masahiro","family":"Hitomi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akshaya","family":"Radhakrishnan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kayla","family":"Klatt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sung Hee","family":"Choi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jay T","family":"Myers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aarshvi","family":"Bhatt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Duncan","family":"Stearns","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Irina","family":"Pateva","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zachary D C","family":"Burke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alex Y","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gary K","family":"Schwartz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Reshmi","family":"Parameswaran","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,3,17]]},"reference":[{"issue":"27","key":"4729_CR1","doi-asserted-by":"publisher","first-page":"3029","DOI":"10.1200\/JCO.2014.59.4895","volume":"33","author":"MS Isakoff","year":"2015","unstructured":"Isakoff MS, Bielack SS, Meltzer P, Gorlick R. Osteosarcoma: current treatment and a collaborative pathway to success. J Clin Oncol. 2015;33(27):3029\u201335.","journal-title":"J Clin Oncol"},{"key":"4729_CR2","doi-asserted-by":"publisher","first-page":"2767","DOI":"10.12688\/f1000research.9465.1","volume":"5","author":"SS Bielack","year":"2016","unstructured":"Bielack SS, Hecker-Nolting S, Blattmann C, Kager L. Advances in the management of osteosarcoma. F1000Res. 2016;5:2767.","journal-title":"F1000Res"},{"issue":"1","key":"4729_CR3","doi-asserted-by":"publisher","first-page":"506","DOI":"10.1186\/s12885-023-11024-9","volume":"23","author":"C Zhang","year":"2023","unstructured":"Zhang C, Wu H, Xu G, Xu Y, Ma W, Li Z, et al. Incidence, survival, and associated factors estimation in osteosarcoma patients with lung metastasis: a single-center experience of 11 years in Tianjin, China. BMC Cancer. 2023;23(1):506.","journal-title":"BMC Cancer"},{"issue":"4","key":"4729_CR4","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1097\/CCO.0b013e328122d73f","volume":"19","author":"S Ferrari","year":"2007","unstructured":"Ferrari S, Palmerini E. Adjuvant and neoadjuvant combination chemotherapy for osteogenic sarcoma. Curr Opin Oncol. 2007;19(4):341\u20136.","journal-title":"Curr Opin Oncol"},{"issue":"9","key":"4729_CR5","doi-asserted-by":"publisher","first-page":"2617","DOI":"10.1007\/s00262-021-02876-w","volume":"70","author":"K Boye","year":"2021","unstructured":"Boye K, Longhi A, Guren T, Lorenz S, N\u00e6ss S, Pierini M, et al. Pembrolizumab in advanced osteosarcoma: results of a single-arm, open-label, phase 2 trial. Cancer Immunol Immunother. 2021;70(9):2617\u201324.","journal-title":"Cancer Immunol Immunother"},{"issue":"11","key":"4729_CR6","doi-asserted-by":"publisher","first-page":"1493","DOI":"10.1016\/S1470-2045(17)30624-1","volume":"18","author":"HA Tawbi","year":"2017","unstructured":"Tawbi HA, Burgess M, Bolejack V, Van Tine BA, Schuetze SM, Hu J, et al. Pembrolizumab in advanced soft-tissue sarcoma and bone sarcoma (SARC028): a multicentre, two-cohort, single-arm, open-label, phase 2 trial. Lancet Oncol. 2017;18(11):1493\u2013501.","journal-title":"Lancet Oncol"},{"issue":"11","key":"4729_CR7","doi-asserted-by":"publisher","first-page":"1002","DOI":"10.1056\/NEJMoa2213614","volume":"388","author":"P Rodriguez-Otero","year":"2023","unstructured":"Rodriguez-Otero P, Ailawadhi S, Arnulf B, Patel K, Cavo M, Nooka AK, et al. Ide-cel or standard regimens in relapsed and refractory multiple myeloma. N Engl J Med. 2023;388(11):1002\u201314.","journal-title":"N Engl J Med"},{"issue":"2","key":"4729_CR8","doi-asserted-by":"publisher","first-page":"e321","DOI":"10.1634\/theoncologist.2019-0233","volume":"25","author":"S Ali","year":"2020","unstructured":"Ali S, Kjeken R, Niederlaender C, Markey G, Saunders TS, Opsata M, et al. The European medicines agency review of Kymriah (Tisagenlecleucel) for the treatment of acute lymphoblastic leukemia and diffuse large B-cell lymphoma. Oncologist. 2020;25(2):e321\u20137.","journal-title":"Oncologist"},{"issue":"26","key":"4729_CR9","doi-asserted-by":"publisher","first-page":"2531","DOI":"10.1056\/NEJMoa1707447","volume":"377","author":"SS Neelapu","year":"2017","unstructured":"Neelapu SS, Locke FL, Bartlett NL, Lekakis LJ, Miklos DB, Jacobson CA, et al. Axicabtagene ciloleucel CAR T-cell therapy in refractory large B-cell lymphoma. N Engl J Med. 2017;377(26):2531\u201344.","journal-title":"N Engl J Med"},{"issue":"14","key":"4729_CR10","doi-asserted-by":"publisher","first-page":"2594","DOI":"10.1200\/JCO.22.01797","volume":"41","author":"Y Wang","year":"2023","unstructured":"Wang Y, Jain P, Locke FL, Maurer MJ, Frank MJ, Munoz JL, et al. Brexucabtagene autoleucel for relapsed or refractory mantle cell lymphoma in standard-of-care practice: results from the US lymphoma CAR T consortium. J Clin Oncol. 2023;41(14):2594\u2013606.","journal-title":"J Clin Oncol"},{"issue":"2","key":"4729_CR11","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1056\/NEJMoa2301665","volume":"389","author":"JR Westin","year":"2023","unstructured":"Westin JR, Oluwole OO, Kersten MJ, Miklos DB, Perales MA, Ghobadi A, et al. Survival with axicabtagene ciloleucel in large B-cell lymphoma. N Engl J Med. 2023;389(2):148\u201357.","journal-title":"N Engl J Med"},{"issue":"10343","key":"4729_CR12","doi-asserted-by":"publisher","first-page":"2294","DOI":"10.1016\/S0140-6736(22)00662-6","volume":"399","author":"M Kamdar","year":"2022","unstructured":"Kamdar M, Solomon SR, Arnason J, Johnston PB, Glass B, Bachanova V, et al. Lisocabtagene maraleucel versus standard of care with salvage chemotherapy followed by autologous stem cell transplantation as second-line treatment in patients with relapsed or refractory large B-cell lymphoma (TRANSFORM): results from an interim analysis of an open-label, randomised, phase 3 trial. Lancet. 2022;399(10343):2294\u2013308.","journal-title":"Lancet"},{"key":"4729_CR13","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1113882","volume":"14","author":"A Daei Sorkhabi","year":"2023","unstructured":"Daei Sorkhabi A, Mohamed Khosroshahi L, Sarkesh A, Mardi A, Aghebati-Maleki A, Aghebati-Maleki L, et al. The current landscape of CAR T-cell therapy for solid tumors: mechanisms, research progress, challenges, and counterstrategies. Front Immunol. 2023;14:1113882.","journal-title":"Front Immunol"},{"key":"4729_CR14","doi-asserted-by":"crossref","unstructured":"Li S, Zhang H, Shang G. Current status and future challenges of CAR-T cell therapy for osteosarcoma. Front Immunol. 2023;14.","DOI":"10.3389\/fimmu.2023.1290762"},{"issue":"5","key":"4729_CR15","doi-asserted-by":"publisher","first-page":"479","DOI":"10.1007\/s11912-023-01380-x","volume":"25","author":"G Guzman","year":"2023","unstructured":"Guzman G, Reed MR, Bielamowicz K, Koss B, Rodriguez A. CAR-T therapies in solid tumors: opportunities and challenges. Curr Oncol Rep. 2023;25(5):479\u201389.","journal-title":"Curr Oncol Rep"},{"issue":"7906","key":"4729_CR16","doi-asserted-by":"publisher","first-page":"563","DOI":"10.1038\/s41586-022-04585-5","volume":"604","author":"RC Larson","year":"2022","unstructured":"Larson RC, Kann MC, Bailey SR, Haradhvala NJ, Llopis PM, Bouffard AA, et al. CAR T cell killing requires the IFN\u03b3R pathway in solid but not liquid tumours. Nature. 2022;604(7906):563\u201370.","journal-title":"Nature"},{"issue":"1","key":"4729_CR17","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1016\/j.ccell.2023.11.012","volume":"42","author":"AB Arnett","year":"2024","unstructured":"Arnett AB, Heczey A. GD2-CAR CAR T-cells in patients with osteosarcoma and neuroblastoma-it\u2019s not only the T cells that matter. Cancer Cell. 2024;42(1):8\u201310.","journal-title":"Cancer Cell"},{"issue":"15","key":"4729_CR18","doi-asserted-by":"publisher","first-page":"1688","DOI":"10.1200\/JCO.2014.58.0225","volume":"33","author":"N Ahmed","year":"2015","unstructured":"Ahmed N, Brawley VS, Hegde M, Robertson C, Ghazi A, Gerken C, et al. Human epidermal growth factor receptor 2 (HER2) -specific chimeric antigen receptor-modified T cells for the immunotherapy of HER2-positive sarcoma. J Clin Oncol. 2015;33(15):1688\u201396.","journal-title":"J Clin Oncol"},{"issue":"3","key":"4729_CR19","doi-asserted-by":"publisher","DOI":"10.1111\/sji.12741","volume":"89","author":"H K\u00f6ksal","year":"2019","unstructured":"K\u00f6ksal H, M\u00fcller E, Inderberg EM, Bruland \u00d8, W\u00e4lchli S. Treating osteosarcoma with CAR T cells. Scand J Immunol. 2019;89(3):e12741.","journal-title":"Scand J Immunol"},{"issue":"39","key":"4729_CR20","doi-asserted-by":"publisher","first-page":"32848","DOI":"10.1074\/jbc.M112.387324","volume":"287","author":"S Chollangi","year":"2012","unstructured":"Chollangi S, Mather T, Rodgers KK, Ash JD. A unique loop structure in oncostatin M determines binding affinity toward oncostatin M receptor and leukemia inhibitory factor receptor. J Biol Chem. 2012;287(39):32848\u201359.","journal-title":"J Biol Chem"},{"key":"4729_CR21","doi-asserted-by":"crossref","unstructured":"Wolf CL, Pruett C, Lighter D, Jorcyk CL. The clinical relevance of OSM in inflammatory diseases: a comprehensive review. Front Immunol. 2023;14:1239732.","DOI":"10.3389\/fimmu.2023.1239732"},{"key":"4729_CR22","doi-asserted-by":"crossref","unstructured":"Araujo AM, Abaurrea A, Azcoaga P, L\u00f3pez-Velazco JI, Manzano S, Rodriguez J, et al. Stromal oncostatin M cytokine promotes breast cancer progression by reprogramming the tumor microenvironment. J Clin Invest. 2022;132(7):e148667.","DOI":"10.1172\/JCI165107"},{"issue":"1","key":"4729_CR23","doi-asserted-by":"publisher","DOI":"10.1186\/s12935-021-02260-9","volume":"21","author":"M Chen","year":"2021","unstructured":"Chen M, Ren R, Lin W, Xiang L, Zhao Z, Shao B. Exploring the oncostatin M (OSM) feed-forward signaling of glioblastoma via STAT3 in pan-cancer analysis. Cancer Cell Int. 2021;21(1):565.","journal-title":"Cancer Cell Int"},{"issue":"1","key":"4729_CR24","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-021-27607-8","volume":"12","author":"BY Lee","year":"2021","unstructured":"Lee BY, Hogg EKJ, Below CR, Kononov A, Blanco-Gomez A, Heider F, et al. Heterocellular OSM-OSMR signalling reprograms fibroblasts to promote pancreatic cancer growth and metastasis. Nat Commun. 2021;12(1):7336.","journal-title":"Nat Commun"},{"issue":"5","key":"4729_CR25","doi-asserted-by":"publisher","first-page":"1782","DOI":"10.1016\/j.ajpath.2012.07.023","volume":"181","author":"E David","year":"2012","unstructured":"David E, Tirode F, Baud\u2019huin M, Guihard P, Laud K, Delattre O, et al. Oncostatin M is a growth factor for Ewing sarcoma. Am J Pathol. 2012;181(5):1782\u201395.","journal-title":"Am J Pathol"},{"key":"4729_CR26","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1186\/1471-2407-11-125","volume":"11","author":"SL Fossey","year":"2011","unstructured":"Fossey SL, Bear MD, Kisseberth WC, Pennell M, London CA. Oncostatin M promotes STAT3 activation, VEGF production, and invasion in osteosarcoma cell lines. BMC Cancer. 2011;11:125.","journal-title":"BMC Cancer"},{"key":"4729_CR27","doi-asserted-by":"crossref","unstructured":"McCollum S, Kalivas A, Kirkham M, Kunz K, Okojie J, Pavek A, et al. Oncostatin M receptor as a therapeutic target for radioimmune therapy in synovial sarcoma. Pharmaceuticals (Basel). 2022;15(6):650.","DOI":"10.3390\/ph15060650"},{"issue":"1","key":"4729_CR28","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-021-27853-w","volume":"13","author":"DP Wong","year":"2022","unstructured":"Wong DP, Roy NK, Zhang K, Anukanth A, Asthana A, Shirkey-Son NJ, et al. A BAFF ligand-based CAR-T cell targeting three receptors and multiple B cell cancers. Nat Commun. 2022;13(1):217.","journal-title":"Nat Commun"},{"key":"4729_CR29","doi-asserted-by":"publisher","first-page":"e2300104","DOI":"10.1200\/CCI.23.00104","volume":"7","author":"DM Yang","year":"2023","unstructured":"Yang DM, Zhou Q, Furman-Cline L, Cheng X, Luo D, Lai H, et al. Osteosarcoma explorer: a data commons with clinical, genomic, protein, and tissue imaging data for osteosarcoma research. JCO Clin Cancer Inform. 2023;7:e2300104.","journal-title":"JCO Clin Cancer Inform"},{"issue":"1","key":"4729_CR30","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-024-59243-9","volume":"14","author":"L Wang","year":"2024","unstructured":"Wang L, Liu Y, Tai J, Dou X, Yang H, Li Q, et al. Transcriptome and single-cell analysis reveal disulfidptosis-related modification patterns of tumor microenvironment and prognosis in osteosarcoma. Sci Rep. 2024;14(1):9186.","journal-title":"Sci Rep"},{"issue":"12","key":"4729_CR31","doi-asserted-by":"publisher","first-page":"773","DOI":"10.1038\/s41577-018-0066-7","volume":"18","author":"SA Jones","year":"2018","unstructured":"Jones SA, Jenkins BJ. Recent insights into targeting the IL-6 cytokine family in inflammatory diseases and cancer. Nat Rev Immunol. 2018;18(12):773\u201389.","journal-title":"Nat Rev Immunol"},{"issue":"51","key":"4729_CR32","doi-asserted-by":"publisher","first-page":"32635","DOI":"10.1074\/jbc.271.51.32635","volume":"271","author":"B Mosley","year":"1996","unstructured":"Mosley B, De Imus C, Friend D, Boiani N, Thoma B, Park LS, et al. Dual oncostatin M (OSM) receptors: cloning and characterization of an alternative signaling subunit conferring OSM-specific receptor activation. J Biol Chem. 1996;271(51):32635\u201343.","journal-title":"J Biol Chem"},{"issue":"52","key":"4729_CR33","doi-asserted-by":"publisher","first-page":"20181","DOI":"10.1074\/jbc.RA118.004375","volume":"293","author":"JM Adrian-Segarra","year":"2018","unstructured":"Adrian-Segarra JM, Sreenivasan K, Gajawada P, L\u00f6rchner H, Braun T, P\u00f6ling J. The AB loop of oncostatin M (OSM) determines species-specific signaling in humans and mice. J Biol Chem. 2018;293(52):20181\u201399.","journal-title":"J Biol Chem"},{"issue":"7502","key":"4729_CR34","doi-asserted-by":"publisher","first-page":"582","DOI":"10.1038\/nature13319","volume":"509","author":"M Wilhelm","year":"2014","unstructured":"Wilhelm M, Schlegl J, Hahne H, Gholami AM, Lieberenz M, Savitski MM, et al. Mass-spectrometry-based draft of the human proteome. Nature. 2014;509(7502):582\u20137.","journal-title":"Nature"},{"issue":"4","key":"4729_CR35","doi-asserted-by":"publisher","first-page":"714","DOI":"10.1111\/os.13243","volume":"14","author":"G Xu","year":"2022","unstructured":"Xu G, Wu H, Zhang Y, Xu Y, Guo X, Baklaushev VP, et al. Risk and prognostic factors for different organ metastasis in primary osteosarcoma: a large population-based analysis. Orthop Surg. 2022;14(4):714\u20139.","journal-title":"Orthop Surg"},{"issue":"3","key":"4729_CR36","doi-asserted-by":"publisher","first-page":"804","DOI":"10.1182\/blood.V93.3.804","volume":"93","author":"M Tanaka","year":"1999","unstructured":"Tanaka M, Hara T, Copeland NG, Gilbert DJ, Jenkins NA, Miyajima A. Reconstitution of the functional mouse oncostatin M (OSM) receptor: molecular cloning of the mouse OSM receptor \u03b2 subunit. Blood. 1999;93(3):804\u201315.","journal-title":"Blood"},{"issue":"2","key":"4729_CR37","doi-asserted-by":"publisher","first-page":"278","DOI":"10.1038\/bjc.2014.585","volume":"112","author":"NC Daw","year":"2015","unstructured":"Daw NC, Chou AJ, Jaffe N, Rao BN, Billups CA, Rodriguez-Galindo C, et al. Recurrent osteosarcoma with a single pulmonary metastasis: a multi-institutional review. Br J Cancer. 2015;112(2):278\u201382.","journal-title":"Br J Cancer"},{"key":"4729_CR38","doi-asserted-by":"crossref","unstructured":"Harris MA, Hawkins CJ. Recent and ongoing research into metastatic osteosarcoma treatments. Int J Mol Sci. 2022;23(7):3817.","DOI":"10.3390\/ijms23073817"},{"issue":"1","key":"4729_CR39","doi-asserted-by":"publisher","first-page":"234","DOI":"10.1093\/rheumatology\/keac300","volume":"62","author":"CP Denton","year":"2022","unstructured":"Denton CP, Del Galdo F, Khanna D, Vonk MC, Chung L, Johnson SR, et al. Biological and clinical insights from a randomized phase 2 study of an anti-oncostatin M monoclonal antibody in systemic sclerosis. Rheumatology (Oxford). 2022;62(1):234\u201342.","journal-title":"Rheumatology (Oxford)"},{"key":"4729_CR40","doi-asserted-by":"publisher","first-page":"886546","DOI":"10.3389\/fimmu.2022.886546","volume":"13","author":"AN Khan","year":"2022","unstructured":"Khan AN, Chowdhury A, Karulkar A, Jaiswal AK, Banik A, Asija S, et al. Immunogenicity of CAR-T cell therapeutics: evidence, mechanism and mitigation. Front Immunol. 2022;13:886546.","journal-title":"Front Immunol"},{"issue":"1","key":"4729_CR41","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1158\/0008-5472.CAN-11-2778","volume":"72","author":"G Huang","year":"2012","unstructured":"Huang G, Yu L, Cooper LJ, Hollomon M, Huls H, Kleinerman ES. Genetically modified T cells targeting interleukin-11 receptor\u00a0\u03b1-chain kill human osteosarcoma cells and induce the regression of established osteosarcoma lung metastases. Cancer Res. 2012;72(1):271\u201381.","journal-title":"Cancer Res"},{"issue":"10435","key":"4729_CR42","doi-asserted-by":"publisher","first-page":"1460","DOI":"10.1016\/S0140-6736(24)00319-2","volume":"403","author":"SP D\u2019Angelo","year":"2024","unstructured":"D\u2019Angelo SP, Araujo DM, Abdul Razak AR, Agulnik M, Attia S, Blay J-Y, et al. Afamitresgene autoleucel for advanced synovial sarcoma and myxoid round cell liposarcoma (SPEARHEAD-1): an international, open-label, phase 2 trial. Lancet. 2024;403(10435):1460\u201371.","journal-title":"Lancet"},{"key":"4729_CR43","doi-asserted-by":"crossref","unstructured":"Mullard A. FDA approves first TCR-engineered T cell therapy, for rare soft-tissue cancer. Nat Rev Drug Discov. 2024;23:731.","DOI":"10.1038\/d41573-024-00134-z"},{"issue":"13_Supplement","key":"4729_CR44","doi-asserted-by":"publisher","first-page":"LB-147","DOI":"10.1158\/1538-7445.AM2019-LB-147","volume":"79","author":"SA Navai","year":"2019","unstructured":"Navai SA, Derenzo C, Joseph S, Sanber K, Byrd T, Zhang H, et al. Abstract LB-147: Administration of HER2-CAR T cells after lymphodepletion safely improves T cell expansion and induces clinical responses in patients with advanced sarcomas. Cancer Res. 2019;79(13_Supplement):LB-147-LB.","journal-title":"Cancer Res"},{"issue":"20","key":"4729_CR45","doi-asserted-by":"publisher","first-page":"5336","DOI":"10.1158\/0008-5472.CAN-21-0483","volume":"81","author":"A Geethadevi","year":"2021","unstructured":"Geethadevi A, Nair A, Parashar D, Ku Z, Xiong W, Deng H, et al. Oncostatin M receptor-targeted antibodies suppress STAT3 signaling and inhibit ovarian cancer growth. Cancer Res. 2021;81(20):5336\u201352.","journal-title":"Cancer Res"},{"issue":"3","key":"4729_CR46","doi-asserted-by":"publisher","first-page":"222","DOI":"10.1080\/07357900701638491","volume":"26","author":"I Garc\u00eda-Tu\u00f1\u00f3n","year":"2008","unstructured":"Garc\u00eda-Tu\u00f1\u00f3n I, Ricote M, Ruiz A, Fraile B, Paniagua R, Royuela M. OSM, LIF, its receptors, and its relationship with the malignance in human breast carcinoma (in situ and in infiltrative). Cancer Invest. 2008;26(3):222\u20139.","journal-title":"Cancer Invest"}],"container-title":["BMC Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12916-026-04729-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12916-026-04729-8","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12916-026-04729-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,17]],"date-time":"2026-03-17T00:03:25Z","timestamp":1773705805000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12916-026-04729-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,17]]},"references-count":46,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["4729"],"URL":"https:\/\/doi.org\/10.1186\/s12916-026-04729-8","relation":{},"ISSN":["1741-7015"],"issn-type":[{"value":"1741-7015","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,17]]},"assertion":[{"value":"24 August 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 February 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 March 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All studies were conducted with the explicit approval of relevant review boards. For animal studies conducted at CWRU, approval from the IACUC was obtained under protocols 2015-0160, 2016-0067, and 2016-0307 with relevant amendments approved as studies evolved. For the generation of the KKOS cell line, case 3Y15 had samples collected per CWRU Institutional Research Board (IRB) approved protocol 08-15-14C. For human tissue collected at the Cleveland Clinic and the establishment of the PDX cell line tested, tissue samples were collected from consented osteosarcoma patients according to the IRB approved protocol (IRB 15-1580) at the Cleveland Clinic, and for PDX establishment, approval from the IACUC at the Cleveland Clinic (IACUC 3142) was obtained. Written informed consent from the relevant parties was obtained prior to any sample being collected and utilized as stated in the approved institutional IRBs.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"RP is a scientific advisory board member of Luminary Therapeutics","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"158"}}